Stryker Co. (NYSE:SYK) Shares Bought by Woodstock Corp

Woodstock Corp raised its stake in Stryker Co. (NYSE:SYK) by 0.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,219 shares of the medical technology company’s stock after buying an additional 151 shares during the quarter. Woodstock Corp’s holdings in Stryker were worth $5,840,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dale Q Rice Investment Management Ltd purchased a new stake in shares of Stryker in the fourth quarter valued at about $587,000. PFW Advisors LLC acquired a new position in Stryker in the 4th quarter valued at about $1,350,000. Parnassus Investments LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at approximately $762,798,000. Baltimore Washington Financial Advisors Inc. increased its holdings in shares of Stryker by 2.4% during the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock worth $24,089,000 after buying an additional 1,554 shares during the last quarter. Finally, Sivik Global Healthcare LLC raised its position in shares of Stryker by 8.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock valued at $9,754,000 after buying an additional 2,000 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $381.32 on Friday. The stock’s 50-day moving average is $375.12 and its two-hundred day moving average is $358.32. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The company has a market cap of $145.36 billion, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95. Stryker Co. has a 1-year low of $307.23 and a 1-year high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter last year, the company earned $2.46 earnings per share. The firm’s revenue was up 11.9% compared to the same quarter last year. Analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Tuesday, December 31st. Stryker’s payout ratio is 36.01%.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. UBS Group increased their price target on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Tuesday, January 7th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group lifted their price target on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.